We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Clinical Drug Investigation 2017 June
Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is efficacious as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Dosage reduction is recommended in patients with intolerable adverse events; however, data regarding the efficacy of low-dose afatinib are limited. We report the case of a 71-year-old female patient who was diagnosed with advanced EGFR-mutated NSCLC and started treatment with oral afatinib 40 mg daily. The patient achieved partial tumor response on computed tomography imaging, but developed unacceptable skin-related toxicities requiring dosage reduction to 20 mg daily. The patient subsequently achieved complete tumor response and showed improvements in performance status. These observations suggest that low-dose afatinib is effective in patients with EGFR-mutated NSCLC who require dosage reduction for intolerable adverse events.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app